PMID- 10653879
OWN - NLM
STAT- MEDLINE
DCOM- 20000229
LR  - 20220330
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 18
IP  - 3
DP  - 2000 Feb
TI  - Alterations of chromosome arms 1p and 19q as predictors of survival in 
      oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas.
PG  - 636-45
AB  - PURPOSE: A recent report suggests that alterations of chromosome arms 1p and 19q 
      are associated with chemotherapeutic response and overall survival in anaplastic 
      oligodendroglioma patients treated with procarbazine, lomustine, and vincristine 
      chemotherapy. We set out to further clarify the diagnostic and prognostic 
      implications of these alterations in a broader set of diffuse gliomas, including 
      astrocytic neoplasms and low-grade oligodendrogliomas. PATIENTS AND METHODS: 
      Fluorescence in situ hybridization (FISH) signals from DNA probes mapping to 1p 
      and 19q common deletion regions were enumerated in 162 diffuse gliomas (79 
      astrocytomas, 52 oligodendrogliomas, and 31 mixed oligoastrocytomas), collected 
      as part of an ongoing prospective investigation of CNS tumors. RESULTS: The 
      oligodendroglial phenotype was highly associated with loss of 1p (P =.0002), loss 
      of 19q (P <.0001), and combined loss of 1p and 19q (P <.0001). Combined loss of 
      1p and 19q was identified as a univariate predictor of prolonged overall survival 
      among patients with pure oligodendroglioma (log-rank, P =.03) and remained a 
      significant predictor after adjusting for the effects of patient age and tumor 
      grade (P <.01). This favorable association was not evident in patients with 
      astrocytoma or mixed oligoastrocytoma. CONCLUSION: Combined loss of 1p and 19q is 
      a statistically significant predictor of prolonged survival in patients with pure 
      oligodendroglioma, independent of tumor grade. Given the lack of this association 
      in patients with astrocytic neoplasms and the previously demonstrated 
      chemosensitivity of oligodendrogliomas, a combined approach of histologic and 
      genotypic assessment could potentially improve existing strategies for patient 
      stratification and management.
FAU - Smith, J S
AU  - Smith JS
AD  - Division of Laboratory Genetics, Division of Anatomic Pathology, Department of 
      Neurology, and Section of Biostatistics, Mayo Clinic and Foundation, Rochester, 
      MN 55905, USA.
FAU - Perry, A
AU  - Perry A
FAU - Borell, T J
AU  - Borell TJ
FAU - Lee, H K
AU  - Lee HK
FAU - O'Fallon, J
AU  - O'Fallon J
FAU - Hosek, S M
AU  - Hosek SM
FAU - Kimmel, D
AU  - Kimmel D
FAU - Yates, A
AU  - Yates A
FAU - Burger, P C
AU  - Burger PC
FAU - Scheithauer, B W
AU  - Scheithauer BW
FAU - Jenkins, R B
AU  - Jenkins RB
LA  - eng
GR  - CA50905/CA/NCI NIH HHS/United States
GR  - CA50910/CA/NCI NIH HHS/United States
GR  - CA64928/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Astrocytoma/diagnosis/*genetics/pathology
MH  - Central Nervous System Neoplasms/diagnosis/*genetics/pathology
MH  - Child
MH  - *Chromosome Deletion
MH  - *Chromosomes, Human, Pair 1
MH  - *Chromosomes, Human, Pair 19
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Oligodendroglioma/diagnosis/*genetics/pathology
MH  - Predictive Value of Tests
MH  - Prospective Studies
MH  - Survival Analysis
EDAT- 2000/02/02 09:00
MHDA- 2000/03/04 09:00
CRDT- 2000/02/02 09:00
PHST- 2000/02/02 09:00 [pubmed]
PHST- 2000/03/04 09:00 [medline]
PHST- 2000/02/02 09:00 [entrez]
AID - 10.1200/JCO.2000.18.3.636 [doi]
PST - ppublish
SO  - J Clin Oncol. 2000 Feb;18(3):636-45. doi: 10.1200/JCO.2000.18.3.636.